Abstract:Abstract Development of new drugs is of high interest for the field of cardiac and cardiovascular diseases, which are a dominant cause of death worldwide. Before being allowed to be used and distributed, every new potentially therapeutic compound must be strictly validated during preclinical and clinical trials. The preclinical studies usually involve the in vitro and in vivo evaluation. Due to the increasing reporting of discrepancy in drug effects in animal and humans and the requirement to reduce the number of animals used in research, improvement of in vitro models based on human cells is indispensable. Primary cardiac cells are difficult to access and maintain in cell culture for extensive experiments; therefore, the human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) became an excellent alternative. This technology enables a production of high number of patient- and disease-specific cardiomyocytes and other cardiac cell types for a large-scale research. The drug effects can be extensively evaluated in the context of electrophysiological responses with a use of well-established tools, such as multielectrode array (MEA), patch clamp, or calcium ion oscillation measurements. Cardiotoxicity, which is a common reason for withdrawing drugs from marketing or rejection at final stages of clinical trials, can be easily verified with a use of hiPSC-CM model providing a prediction of human-specific responses and higher safety of clinical trials involving patient cohort. Abovementioned studies can be performed using two-dimensional cell culture providing a high-throughput and relatively lower costs. On the other hand, more complex structures, such as engineered heart tissue, organoids, or spheroids, frequently applied as co-culture systems, represent more physiological conditions and higher maturation rate of hiPSC-derived cells. Furthermore, heart-on-a-chip technology has recently become an increasingly popular tool, as it implements controllable culture conditions, application of various stimulations and continuous parameters read-out. This paper is an overview of possible use of cardiomyocytes and other cardiac cell types derived from hiPSC as in vitro models of heart in drug research area prepared on the basis of latest scientific reports and providing thorough discussion regarding their advantages and limitations.

Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery

Human Induced Pluripotent Stem Cell for Modeling Cardiovascular Diseases.

Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy

Human-induced Pluripotent Stem Cells As Models for Rare Cardiovascular Diseases: from Evidence-Based Medicine to Precision Medicine

The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing

Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies

Human pluripotent stem cell-based models of heart development and disease

Perspective on Human Pluripotent Stem Cell-Derived Cardiomyocytes in Heart Disease Modeling and Repair

Advances in the Generation of Constructed Cardiac Tissue Derived from Induced Pluripotent Stem Cells for Disease Modeling and Therapeutic Discovery

Human Pluripotent Stem Cell-Derived Cardiovascular Cells: From Developmental Biology to Therapeutic Applications

Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research

Differentiation And Application Of Human Pluripotent Stem Cells Derived Cardiovascular Cells For Treatment Of Heart Diseases: Promises And Challenges

Current advances in human-induced pluripotent stem cell-based models and therapeutic approaches for congenital heart disease

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

Modelling neurocardiac physiology and diseases using human pluripotent stem cells: current progress and future prospects

A Review of Human Pluripotent Stem Cell-Derived Cardiomyocytes for High-Throughput Drug Discovery, Cardiotoxicity Screening, and Publication Standards

Applications of Genetically Engineered Human Pluripotent Stem Cell Reporters in Cardiac Stem Cell Biology

Application of Pluripotent Stem Cells in Cardiac Development and Disease Research

Modeling Cardiac Disease Mechanisms Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Progress, Promises and Challenges

Induced pluripotent stem cells for cardiovascular therapeutics: Progress and perspectives

Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes